Company Profile

Stratatech Corporation is a regenerative medicine company focused on the development of cell-based, tissue-engineered products for wound care. We are a privately held, Delaware corporation in Madison, Wisconsin. We have a biologically-active wound care product in clinical trials and a development pipeline of wound care products engineered to improve healing and reduce infection in the wound bed.

Stratatech was founded by Professor Lynn Allen-Hoffmann, Ph.D. in 2000 to commercialize a unique opportunity to produce therapeutic, biologically-active wound care products. Professor Allen-Hoffmann and her staff at the University of Wisconsin-Madison School of Medicine and Public Health discovered the NIKS™ human keratinocyte cell line and demonstrated that when properly cultured, the NIKS™ cells form skin.

Stratatech specializes in human tissue substitutes generated with NIKS™ keratinocytes and cells derived from them for biological therapies. Stratatech has exclusive, worldwide commercialization rights in all fields of use to the original NIKS™ cell line patent issued to the Wisconsin Alumni Research Foundation (WARF) and to six subsequent NIKS™ cell line related patents filed by WARF. In addition Stratatech has two issued and numerous pending patents related to this core technology.

StrataGraft™ skin tissue, Stratatech Corporation’s first product is currently in cGMP production and has been approved by the US FDA for application to human patients in a Phase I/II clinical trial. The ExpressGraft™ pipeline of products is the second generation of enhanced wound care therapies being developed by the Company using genetically modified NIKS™ cells.

Stratatech offices and laboratories are located in the University Research Park in Madison, Wisconsin. Stratatech currently has approximately thirty employees, including five Ph.D.s. Over thirty percent of our employees hold advanced degrees.